Jon Collins, PharmD is a Senior Director within the ViiV Clinical Pharmacology division. He received his PharmD from the University of North Carolina-Chapel Hill (UNC) in 2014 after which he completed a joint pharmacology/pharmacometrics fellowship with UNC and GlaxoSmithKline (GSK).
He then worked within the clinical pharmacology groups at Parexel, Roivant Sciences, and Immunovant, where he was Director of clinical pharmacology. In 2019, he transitioned to the clinical pharmacology modeling and simulation oncology group at GSK, providing pharmacometric and model-based meta-analysis support for the submission of Belantamab Mafodotin. He then moved to ViiV, where his primary area of focus is in providing strategic direction for all stages of drug development.
He has extensive experience in authoring regulatory documents across all phases of drug development and has contributed towards the clinical pharmacology/pharmacometric regulatory submissions for four approved drugs in a diverse range of therapeutic areas.
